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 81 
Abstract 82 
Background: Venom-induced anaphylaxis is a common, potentially life-threatening 83 
hypersensitivity reaction associated with specific: 1) symptom profile, 2) cofactors, and 3) 84 
management. Identifying the differences in phenotypes of anaphylaxis is crucial for future 85 
management guidelines and the development of a personalized medicine approach. 86 
Objective: This study aimed to evaluate the phenotype and risk factors of venom-induced 87 
anaphylaxis. 88 
Methods: Using data from the European Anaphylaxis Registry (12874 cases) we identified 89 
3612 patients with venom-induced anaphylaxis and analyzed these in comparison to sex- 90 
and age- matched anaphylaxis cases triggered by other elicitors (non-VIA n = 3605).  91 
Results: Venom-induced anaphylaxis more frequently involved more than three organ 92 
systems and was associated with cardiovascular symptoms. The absence of skin symptoms 93 
during anaphylaxis correlated with baseline serum tryptase and was associated with an 94 
increased risk of a severe reaction. Intramuscular or intravenous epinephrine was 95 
administered significantly less often in venom-induced anaphylaxis, in particular in 96 
patients without prior history of anaphylaxis. Baseline serum tryptase within the upper 97 
normal range (8-11.5 ng-ml) was more frequently associated with severe anaphylaxis. 98 
Conclusion: Using a large cohort of VIA cases, we have validated that patients with 99 
intermediate baseline serum tryptase levels (8 - 11 ng/ml) and without skin involvement 100 
have higher risk of severe VIA. Patients receiving beta-blockers or ACE-I had a higher risk 101 
of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-102 
VIA cases. Patients undergoing VIA received epinephrine less frequently than non-VIA 103 
cases. 104 
Clinical Implications 105 
Allergologists should educate patients about risk of future reactions, consider prescribing 2 106 
epinephrine autoinjectors, and performing SIT in patients with baseline serum tryptase of 107 
above eight ng/ml and a history of insect venom anaphylaxis without skin involvement.  108 
Capsule Summary 109 
Venom-induced anaphylaxis significantly more often presented with cardiovascular 110 
symptoms. Severe cases more often showed lack of skin involvement and were associated 111 
with higher levels of baseline serum tryptase (in range from 8 - 11 ng/ml). 112 




Hypersensitivity to insect venom presents as a systemic reaction (anaphylaxis) in up to 117 
0.3–7.5% of the adult population1. Venom-induced anaphylaxis (VIA) can be fatal, and 118 
patients sometimes require lifelong specific immunotherapy2. There is a need for more 119 
precise identification of biomarkers, and better definition of phenotypes of anaphylaxis3. 120 
Also, in order to facilitate a precision-medicine approach4 for the diagnosis of anaphylaxis, 121 
a better understanding of its clinical phenotypes is required. 122 
Anaphylaxis is a clinical diagnosis with a variety of triggering factors and clinical 123 
presentations. Symptom profiles and specific cofactors for venom-induced anaphylaxis 124 
(VIA) had previously been analyzed in an uncontrolled manner, albeit in relatively small 125 
cohorts5–7. 126 
Controlled clinical trials in anaphylaxis are difficult to conduct due to the acuteness of this 127 
life-threatening condition and its infrequent and random occurrence. Therefore registries, 128 
gathering clinical data from patients with a well-documented (recent) history of 129 
anaphylaxis are crucial in investigating this entity. 130 
This study aimed to identify clinical patterns of VIA regarding symptoms, cofactors, and 131 
management by a case-control comparison with other types of anaphylaxis (non-VIA) 132 
based on the data from the European Anaphylaxis Registry. 133 
Methods 134 
We searched the European Anaphylaxis Registry8 (status until March 2019) for 135 
anaphylaxis cases elicited by insect venom. The flowchart in Fig. 1A represents the detailed 136 
case-selection process. 137 
The diagnosis of anaphylaxis was based on the definition by NIAID/FAAN9 and the severity 138 
according to the Ring and Messmer Scale10. Reactions of grade II were considered mild and 139 
grades III and IV (presenting with significant hypoxia, hypotension, confusion, and loss of 140 
consciousness, or incontinence or cardiac arrest) were considered severe. Mastocytosis 141 
patients were defined as having a documented diagnosis of mastocytosis in medical history 142 
prior to the reaction. The Registry is designed for reporting cases of moderate to severe 143 
anaphylaxis (Ring and Messmer grades II-IV). 144 
Due to a large number of documented reactions in the European Anaphylaxis Registry, we 145 
were able to match the VIA with non-VIA cases according to sex and age. When we 146 
analyzed a density plot of VIA cases according to age, we determined a bimodal distribution 147 
forming two subsets of patients with a cutoff age of 22 (Fig. 1B). Subsequently, we 148 
compared the management in both groups and matched the control group according to the 149 
severity of a reaction. 150 
Cases were matched according to sex, age, and reaction severity in order to reduce the 151 
comparison bias by propensity score matching. Propensity score is a statistical approach to 152 
quantify the similarity between two unrelated cases. Propensity scores were calculated 153 
using the “MatchIt” package for R11. MatchIt uses logistic regression to reduce the bias due 154 
to multiple confounding variables (i.e. sex and age) by weighing them and choosing cases 155 
with minimal differences in both groups. The results of the propensity score matching are 156 
illustrated in Fig. 1B-D and eFig. 2. 157 
The final database included 3612 cases of venom-induced anaphylaxis reported from 158 
allergy centers in 11 countries and sex- and age-matched control group. We compared the 159 
frequency of various symptoms, cofactors — known to increase the risk of severe 160 
anaphylaxis,12, and management in both groups. 161 
Based on the severity and symptom profile and the previous reports6, we defined sub-162 
elevated baseline serum tryptase (BST) values as 8 - 11.5 ng/ml (Fig. 3C-D). 163 
We used the R Statistical Package13 for statistical analysis. A simple comparison of 164 
categorical variables was performed using either the Chi2 test or Fisher’s exact test (where 165 
the number of observations in a bin was less than 10). Continuous variables were analyzed 166 
using the Mann-Whitney U test. In case of comparisons with two or more independent 167 
variables, we used Factorial ANOVA or Generalized Linear Models. We defined statistical 168 
significance as α = 0.05. Data, along with the analysis script, can be accessed online at 169 
https://github.com/wolass/venomanaphylaxiscompendium. 170 
We developed a Random Forest classifier (using the “randomForest” package for R14) in 171 
order to find therapeutic approaches that varied the most between VIA / non-VIA group 172 
and presented the results as Gini importance15. Moreover, association analysis of 173 
therapeutic interventions and symptoms was performed. The resulting phi values were 174 
scaled and presented in a heatmap with automatic clustering using Ward’s Agglomerative 175 
Hierarchical Clustering with Euclidean distances16. 176 
Results 177 
VIA is more frequently associated with cardiovascular symptoms 178 
VIA displayed a specific symptom pattern. Patients, who underwent VIA, more often 179 
experienced cardiovascular symptoms (dizziness, hypotension, unconsciousness, reduced 180 
alertness) than patients with anaphylaxis due to other elicitors and less often presented 181 
with respiratory distress, rhinitis or diarrhea (Fig. 2A). 182 
Although the pattern of organ involvement during anaphylaxis in both groups showed 183 
similarities in gastrointestinal, skin, and respiratory systems, VIA more frequently involved 184 
more than three organ systems (2356 (65.4%) vs. 2023 (56.1%), p < 0.001), and 185 
predominantly involved cardiovascular system (2984 (82.8%) vs. 2244 (62.2%) p < 0.001 186 
Fig. 2B). 187 
Younger patients (under 22) presented even more prominent differences in hypotension 188 
symptoms and significantly less frequently reported gastrointestinal symptoms (e.g., 189 
vomiting) when the reaction was triggered by insect venom (Fig. 2C-E). 190 
Absence of skin symptoms during anaphylaxis is associated with more 191 
severe episodes of VIA 192 
We found that 74 (54.4%) of patients with concomitant mastocytosis had anaphylaxis 193 
without skin symptoms (i.e., urticaria and flushing), which was significantly more frequent 194 
compared to patients without diagnosed mastocytosis (2031; 30.7%, p < 0.001). This 195 
finding was most prominently seen in VIA (Fig. 3A). 196 
Similarly, in non-mastocytosis patients undergoing VIA, skin symptoms (i.e., urticaria or 197 
flushing) were less often present than if anaphylaxis was triggered by other elicitors (2356; 198 
68% vs. 2495; 70.4% respectively, p = 0.031). Moreover, in this specific subgroup of 199 
patients (i.e., non-mastocytosis patients lacking skin symptoms) VIA was significantly more 200 
frequently severe (587; 52.9% in VIA vs. 498; 47.4%, p < 0.001, Fig. 3B). 201 
By applying factorial logistic regression modeling (Table S1), we confirmed a significant 202 
interaction effect between the presence of skin symptoms and insect venom on the severity 203 
of anaphylaxis (p < 0.001). In other words, non-mastocytosis patients presenting without 204 
urticaria or flushing tended to have more severe anaphylaxis when triggered by insects. 205 
(Fig. 3B, and Tab. S1). 206 
Absence of skin symptoms correlates with BST levels and increases 207 
the risk of severe anaphylaxis specifically in VIA 208 
BST levels were significantly higher in patients with a prior diagnosis of mastocytosis (eFig. 209 
7). We investigated the association of skin symptoms with the tryptase levels in non-210 
mastocytosis patients. For this model, we excluded the cases with known mastocytosis and 211 
with BST above 11.5 ng/ml, potentially indicating non-diagnosed mast cell activation 212 
disorders. Similarly, 1) tryptase levels were higher in VIA patients, 2) correlated with the 213 
severity of anaphylaxis, and 3) this effect was significant in VIA (p = 0.006) but not in the 214 
non-VIA group (Fig. 3C-D). 215 
BST over 8 ng/ml and concomitant cardiovascular conditions increase 216 
the risk of severe VIA 217 
The cofactor most prominently associated with an increased risk of severe anaphylaxis was 218 
mastocytosis (Fig. 4). Concomitant mastocytosis increased the risk for 1) cardiac arrest and 219 
2) loss of consciousness in patients undergoing VIA significantly more than in patients 220 
undergoing anaphylaxis due to other elicitors (Fig. 4C and eFig. 3A). 221 
In line with the findings above, BST levels also correlated with the severity of anaphylaxis 222 
(on the Ring and Messmer scale) and, most importantly, sub-elevated BST was more 223 
prominently associated with increasing the risk of severe anaphylaxis in VIA than in non-224 
VIA (Fig. 2D and Fig. 4B). 225 
Concomitant cardiovascular diseases were more prevalent in VIA than in non-VIA cases 226 
(892 (24.8%) vs. 657 (18.2%)) and were associated with higher risk of severe anaphylaxis 227 
when elicited by insects but were not relevant in non-VIA cases (Fig. 4). Interestingly, BST 228 
values were increased in patients with concomitant cardiovascular diseases, irrespectively 229 
of the reaction severity (eFig. 4). 230 
Other cofactors of severe reactions 231 
Severe reactions of VIA were more prevalent in patients above 22 years of age, and in VIA 232 
cases vs. non-VIA cases (eFig. 5). There were no differences in severity of reactions elicited 233 
by yellow-jackets and other insect species (p = 0.4128). 234 
The effect of using ACE-I (as well as beta-blockers) on the risk of severe anaphylaxis 235 
correlated with coexisting cardiovascular diseases. ACE-I use was, however, more often 236 
associated with cardiac arrests in all anaphylaxis cases (30 (5.8%) vs. 118 (1.9%), p < 237 
0.001) regardless of the elicitor (Fig. 4C). Beta-blocker use was associated with a higher 238 
severity of anaphylaxis and with the onset of cardiovascular symptoms (cardiac arrest, 239 
chest pain), but was comparable between both VIA and non-VIA, p = 0.144). Surprisingly, 240 
arrhythmia was more frequently reported in patients with VIA and concomitant beta-241 
blockers (Fig. 4C). 242 
IVA was more often severe if the reaction occurred in the first 10 minutes after exposure to 243 
venom (46.58% were severe cases) then when the reaction occurred after 10 minutes post 244 
exposure (39.75% were severe cases, p = 0.001). 245 
One-third of VIA patients experience repeated reactions 246 
940 (28.5%) of patients with insect allergy had experienced venom anaphylaxis in the past. 247 
If the reaction was elicited by other elicitors (i.e., non-VIA) — previous reactions were 248 
more frequently seen (1929; 35.7%, p < 0.001). We observed 227 patients with at least two 249 
fully-documented reactions. Out of these 59 (26%) had insect elicited anaphylaxis and in 6 250 
of them (10.2%), the following reaction was more severe than before. In 43 (72.9%) cases, 251 
the reaction was similar in severity. 252 
VIA patients receive epinephrine less often than non-VIA 253 
We evaluated epinephrine use (administered by any route from patients themselves and 254 
medical professionals) in both ambulatory and emergency room settings. 255 
Patients who underwent VIA significantly less often received epinephrine treatment than 256 
in other anaphylaxis cases (597; 26.9% vs. 738; 34.6%, p < 0.001). After adjusting both 257 
groups for similar severity - the difference in epinephrine use was still significant 258 
irrespective of the administration route (p < 0.001, Fig 5B).  259 
A positive history of anaphylaxis influenced the therapy of a current episode as well. 260 
Epinephrine as a first-line treatment was given less often in VIA cases when compared to 261 
other cases if patients did not report a previous history of anaphylaxis (p < 0.001), but 262 
in patients reporting previous reactions, there was no difference in epinephrine therapy (p 263 
= 0.438, Fig. 5B). Similarly, there were no differences in the epinephrine use between VIA 264 
and non-VIA when only severe reactions were taken into consideration (p = 0.242). 265 
However, when we restricted the analysis to moderate anaphylaxis cases — non-VIA 266 
patients received epinephrine more frequently than VIA (p < 0.001). The presence of skin 267 
symptoms during these mild reactions also was associated with a lower fraction of 268 
epinephrine treated patients (eFig. 6). 269 
Patients with VIA received corticosteroids and antihistamines significantly more frequently 270 
than patients with anaphylaxis to other elicitors. On the other hand, epinephrine, beta-2 271 
mimetics, and oxygen were given more often to patients suffering from non-VIA (Fig. 5A). 272 
Next, we asked whether specific symptom clusters and treatment profiles could be 273 
identified within our cohort (association measured using phi coefficient). We found that 274 
patients displaying cardiovascular symptoms (cardiac arrest, hypotension, loss of 275 
consciousness) and urticaria were treated differently than patients with respiratory or 276 
gastrointestinal symptoms (Fig. 5C). The treatment of the former symptoms consisted of 277 
epinephrine autoinjector (EAI) use, i.v. epinephrine in multiple doses, 100% oxygen 278 
inhalation, an initial dose of antihistamines, and inhaled β-2 agonists. Corticosteroids, i.v. 279 
volume replacement, and i.v. β-2 agonists formed another therapy mode. 280 
Discussion 281 
In this study, we identified distinct symptom-profile and treatment patterns of venom-282 
induced anaphylaxis. The data unraveled phenotypes of VIA, which may support the 283 
development of tools incorporating clinical data for predicting the severity of future 284 
episodes of anaphylaxis. 285 
VIA was more often associated with cardiovascular symptoms than non-VIA. Previous 286 
studies suggest an essential link between the cardiovascular system and insect sting 287 
hypersensitivity7,12,17. VIA has been associated with Kounis syndrome (coronary arterial 288 
spasm induced by the release of mast cell mediators18,19) and cardiac arrhythmias usually 289 
occurring in patients with preexisting heart disease20. 290 
The rate of concomitant cardiovascular diseases was higher in VIA than non-VIA. They are 291 
an essential cofactor increasing the risk of a severe reaction if Hymenoptera elicited the 292 
anaphylaxis. This association was not significant in anaphylaxis elicited by other elicitors. 293 
Notably, cardiac arrest occurred more frequently in patients with elevated BST (> 8 ng/ml), 294 
especially in VIA. Nevertheless, the pathomechanism promoting cardiovascular symptoms 295 
in VIA requires further investigation. 296 
As cardiovascular symptoms like hypotension, collapse, or cardiac arrest lead to a higher 297 
grade on the Ring and Messmer scale than skin or gastrointestinal symptoms, VIA (being 298 
associated with cardiovascular symptoms) is likely to be associated with more severe 299 
anaphylaxis. 300 
Importantly, the absence of skin symptoms was associated with more severe VIA, which 301 
was still present after excluding patients with a known diagnosis of mastocytosis (although 302 
in non-mastocytosis cases the difference between groups was small and the clinical 303 
relevance of this needs cautious evaluation). Previous studies also observed this 304 
phenomenon21,22. Subsequently, the correlation of BST levels with the severity of 305 
anaphylaxis lead us to identify an interaction between the absence of skin symptoms and 306 
VIA using generalized linear regression. 307 
Our findings indicate that patients with BST above 8 ng/ml are prone to severe anaphylaxis 308 
to insect venom. Patients with normal BST in the range of 8-11.4 ng/ml may have indolent 309 
systemic mastocytosis or concomitant undiagnosed mast cell activation syndrome 310 
(MCAS)23. Zanotti et al. identified mast cell disorders in 17 out of 22 patients with VIA 311 
lacking skin symptoms and concluded that patients with BST above 7.95 ng/ml and VIA 312 
should undergo extensive diagnostic procedures24. We recently identified that elderly 313 
patient undergoing anaphylaxis without concomitant skin symptoms tended to have more 314 
severe reactions25. Our finding are in concordance with a recent retrospective study from 315 
Fehr et al.22 who identified lack of skin symptoms as a risk factor for severe VIA. 316 
Based on these and previous findings6,24,26 we propose to perform a peripheral blood KIT 317 
D816V mutation test in cases of BST of above 8 ng/ml and with a history of anaphylaxis 318 
presenting without urticaria or flushing. Previous studies showed 92% sensitivity of this 319 
test in patients with hymenoptera anaphylaxis, presenting without skin symptoms and 320 
with tryptase under 20 ng/ml27. 321 
Age is an important risk factor for severe anaphylaxis28. Adult patients experienced VIA 322 
more frequently. Young patients mainly suffer from food-induced anaphylaxis8. Emergency 323 
room (ER) admission data indicate that the frequency of insect stings hypersensitivity 324 
reactions in children is comparable to food hypersensitivity reactions (12-15% of cases of 325 
hypersensitivity reactions admitted to the ER), but pediatric anaphylaxis is triggered 326 
significantly more often by food elicitors (56% of food hypersensitivity cases vs. 5.3% of 327 
sting cases seen in the ER)29. Senior patients, on the other hand, suffer from drug-related 328 
hypersensitivity more often than insect sting hypersensitivity25.  Similarly, we observed 329 
less VIA in patients with concomitant atopic diseases (eFig. 3) , as these patients more often 330 
present with food anaphylaxis30. 331 
The role of cardiovascular medication cannot be isolated from the effect of concomitant 332 
cardiovascular conditions; therefore, we cannot state whether ACE-I and beta-blockers 333 
increase the severity of anaphylaxis. However, we did observe that there were no 334 
significant differences between VIA and non-VIA cases regarding the symptoms and 335 
severity of an episode with concomitant use of ACE-I or beta-blockers. 336 
Cases of VIA had been treated with epinephrine less often than the age- sex- and severity-337 
matched cases of non-VIA. Moreover, the administration of epinephrine did not depend on 338 
the trigger if the patient experienced anaphylaxis previously, but was significantly less 339 
often used if the patients experienced their first episode of VIA (in comparison to non-VIA). 340 
The difference between groups was prominent for milder cases of anaphylaxis. The reason 341 
for this observation is unclear. One explanation could be that emergency team more often 342 
attributed the VIA symptoms to anxiety, whereas in non-VIA, they were more often 343 
suspecting anaphylaxis. A second possibility could be that many physicians fail to diagnose 344 
anaphylaxis when no skin symptoms are present. To our knowledge, this is the only data on 345 
the comparative epinephrine usage in a case-controlled group of VIA vs. non-VIA. 346 
Nevertheless, international guidelines of anaphylaxis state that epinephrine (i.m.) is the 347 
first-line agent in all diagnosed cases of anaphylaxis31. Clinicians should not underestimate 348 
the less severe VIA cases and treat them with epinephrine accordingly. 349 
Although there are no absolute contraindications for using epinephrine in anaphylaxis, one 350 
potential scenario where clinicians tend to be reluctant to using epinephrine is a 351 
hypersensitivity reaction presenting with high blood pressure and tachycardia, which may 352 
be present at the initial phase of VIA. Nevertheless, the three exceptionally well 353 
documented cases of anaphylaxis upon sting challenge showed that the initial transient 354 
increase in blood pressure should not be interpreted as a contraindication to epinephrine 355 
and it could be safely given even if the heart rate was above 120 beats per minute32. 356 
IVA patients had a documented history of anaphylaxis in 28% of the cases, and systemic 357 
immunotherapy has not been initiated in these patients, what is against latest management 358 
guidelines, although this fraction may be slowly decreasing it is of utmost importance to 359 
recommend SIT to all patients who experienced VIA.  360 
Based on our findings, insects are the most probable elicitor of anaphylaxis in Europe 361 
during summer-season, with VIA cases extending from early spring to the end of autumn 362 
(eFig. 1). Detailed information on the seasonality of insect-elicited hypersensitivity 363 
reactions is scarce33. The activity of Vespula germanica depends on the climate, and in 364 
invaded regions (e.i. Australia), it can even extend throughout the year34. The changing 365 
climate in Europe may influence the activity of Hymenoptera in this region in the upcoming 366 
years. However, in the period from 2007 - 2019, the perennial ratio of VIA to non-VIA cases 367 
has remained unchanged (data not shown). 368 
Limitations 369 
Due to the design of the European Anaphylaxis Registry, our analysis was restricted only to 370 
cases of anaphylaxis. Milder hypersensitivity reactions, as well as healthy controls, are not 371 
included in the database. Although The European Anaphylaxis Registry is ideal for 372 
investigating anaphylaxis phenotypes - it might give an incomplete perception of the 373 
populational distribution of hypersensitivity reactions and restricts us to only comparing 374 
various forms of anaphylaxis. 375 
Nevertheless, because the European Anaphylaxis Registry has until now gathered over 376 
12,000 cases of anaphylaxis - it was possible to perform a case-controlled analysis on a 377 
relatively large number of cases and investigate many aspects of VIA. It is worth 378 
underlining the important function of international registries, especially in diseases where 379 
targeted studies are not possible. 380 
Conclusion 381 
Based on our results, VIA is a distinctive phenotype of anaphylaxis, with a specific symptom 382 
profile and risk factors. Using a large cohort of VIA cases compared to sex and age matched 383 
non-VIA cases, we have validated that patients with intermediate baseline serum tryptase 384 
levels (8 - 11 ng/ml) and without skin involvement have higher risk of severe VIA. 385 
Similarly, patients receiving beta-blockers or ACE-I had higher risk of developing severe 386 
cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients 387 
undergoing VIA received epinephrine less frequently than non-VIA cases. 388 
VIA cases should undergo therapy according to the international management guidelines, 389 
and epinephrine should be given more often in VIA. All cases should undergo appropriate 390 
allergological testing and indication for SIT should be evaluated along with patient 391 
education regarding the risk of future anaphylaxis. Patients with BST above 8 ng/ml should 392 
undergo extensive diagnostic tests to exclude indolent systemic mastocytosis or MCAS and 393 
should be provided with two EAIs for acute self-management. 394 
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Figure legends 556 
 557 
Figure 1: A) Flow-diagram illustrating the rationale for case inclusion and exclusion from the 558 
final analysis. B, C, D: Age, sex, and severity distribution was matched in cases in both groups 559 
to allow for comparable results between VIA and non-VIA cases. Two age-subsets of patients 560 
could be recognized based on the density plot of age (B). 561 
 562 
Figure 2: Symptoms of venom-induced anaphylaxis (VIA) compared to other elicitors. A: 563 
Proportional presentation of specific reaction symptoms in VIA and non-VIA according to 564 
cardiovascular (cardio.), gastroenterologic (gastro.), and respiratory (resp.) organ systems. B: 565 
High-level overview of involved organ systems and selected cofactors in the form of a radar 566 
plot. C: difference in symptoms of VIA among patients under 22 and over 22 years of age. * 567 
denotes significant differences between groups. 568 
 569 
Figure 3: Lack of skin symptoms (i.e., urticaria and flushing) during anaphylaxis is associated 570 
with more severe VIA. A: lack of skin symptoms and mastocytosis in VIA and non-VIA cases. B: 571 
Lack of skin symptoms, according to the severity in both anaphylaxis groups. C: Relation of 572 
reaction severity according to the elicitor and the absence of skin symptoms concerning 573 
categorized BST values. D: Continous values of BST according to the severity in both non-VIA 574 
and VIA with subgrouping to skin symptoms. 575 
 576 
Figure 4: Cofactors of insect venom anaphylaxis. A: Odds ratios of eliciting severe anaphylaxis. 577 
B: Proportion of cases elicited by insects or other elicitors (upper panels) according to 578 
tryptase levels and cardiovascular symptoms. 579 
 580 
Figure 5: Therapy in patients with VIA compared to other elicitors, cases matched according 581 
to sex, age, and severity of a reaction. A: Proportional use of therapy measures in both 582 
anaphylaxis groups. B: C: Heatmap visualizing the association of symptoms and 583 
corresponding treatment - presented as a scaled correlation coefficient (phi). * - p-value < 584 














Supplementary Figures (online-only material) 
Insect venom anaphylaxis is a seasonal disease.  
VIA in contrast to other elicitors showed a significant seasonal fluctuation and was most 
frequently reported from May to October. The proportion of VIA to anaphylaxis cases 
elicited by other elicitors during the summer seasons reached 60% and was below 1% of 
cases during winter. Nevertheless, 116 cases of VIA (bee – Apis mellifera in spring; yellow 
jacket – Vespula spp. in autumn) were triggered in March, April, and November. Yellow-
jacket was the most prominent VIA-causing insect followed by bees. The VIA-causing insects 
differed in European countries with hornets (Vespa crabro) being more prominent in 
southern Europe. 
 
eFig. 1: A: Proportion of anaphylaxis cases elicited by specific insects according to the month 
in which the reaction occurred. Less common insect species grouped as ‘other’. B: The density 
distribution of VIA cases to cases elicited by other elicitors considering the patient’s age. C: 
Geographical differences in the most common elicitors of VIA. Countries which reported less 
than 10 VIA cases were not illustrated in this figure. Fire ants and insects that could not be 
identified formed the ‘other’ group. 
 
eFig. 2: Results of matching the cohort according to sex and age in order to perform a case-
controlled study. A: The original distribution of VIA and non-VIA cases according to age group 
and sex. Please note the uneven distribution of VIA and non-VIA cases in age groups. B: The 
distribution of VIA and non-VIA after age and sex matching with the use of MatchIt package 
for R. Please notice how the ratio of VIA to non-VIA cases is approaching 50% indicating 
balanced matching according to sex and age variables. 
 
eFig. 3: Symptoms of anaphylaxis. A: The association between cardiac arrest and 
concomitant mastocytosis in VIA and non-VIA. B: Hypotension frequency in two age groups of 
anaphylaxis. C: Crammer’s V as the measure of association between groups anaphylaxis (VIA 
vs. non-VIA). Higher values indicate stronger association with IVA. 
 
eFig. 4: Tryptase levels in patients with concomitant cardiovascular diseases. Low < 4 ng/ml, 
medium 4-8 ng/ml, high 8-11.5 ng/ml. 
 
 eFig. 5: Severity of anaphylaxis in subgroups. The severity of patients with VIA in two age 
groups (left), according to elicitor type (center) and according to the responsible insect 
species (right) 
eFig. 6: Therapy of anaphylaxis. A: Patients who presented with skin symptoms and VIA less 
often received epinephrine than if skin symptoms were absent during the reaction. B: 
Variable importance in the unsupervised classification between VIA and non-VIA using 
Random Forest classifier. 
eFig. 7: Levels of baseline serum tryptase in patinent with VIA and non-VIA. Significant 
difference in BST between patients with concomitant mastocytosis and other patients (***). 
There was no significant difference between anaphylaxis elicited by insects and other elicitors 
(NS). Tested by two way ANOVA. 
 
 
Table S1: The results of a factorial logistic regression. Regression coefficients. 
 
 Dependent variable: 



















Log Likelihood -4,688.151 
Akaike Inf. Crit. 9,384.303 
Note: 
***
p<0.01 
 
